



Publikationen

2018

Krauter J,...**Reimer P**,... Heuser M.

Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in untreated patients with acute myeloid leukemia and high risk for induction failure (AMLSG 17-10 CIARA trial).

Accepted in Br J Hematol (07/2018).

Avivi I,...**Wattad M**,... Conconi A.

High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO.

Br J Haematol (2018) [Epub ahead of print].

Gaidzik VI,...**Wattad M**, ...Döhner K; German-Austrian Acute Myeloid Leukemia Study Group (AMLSG).

DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia.

Leukemia (2018); 32(1): 30-37.



2017

Baertsch, MA, ... **Reimer, P**, ... Wuchter, P.

Cyclophosphamide based stem cell mobilization in relapsed multiple myeloma patients: a subgroup analysis from the phase III trial ReLApsE.

Eur J Haematol (2017); 99(1): 42-50.

Huhn, S, ... **Reimer, P**, ... Goldschmidt, H.

Circulating Tumor Cells as Biomarker for Response to Therapy In Multiple Myeloma Patients Treated Within the GMMG MM5 Trial.

Bone Marrow Transplant (2017); 52(8): 1194-1198.

Kharfan-Dabaja, MA, ... **Reimer, P**, ... Savani, BN.

Clinical practice recommendations on indication and timing of hematopoietic cell transplantation in mature T-cell lymphomas on behalf of the guidelines committee of the American Society for Blood and Marrow Transplantation.

Biology of Blood and Marrow Transplantation (2017); 23(11): 1826-1838.

Wattad M, ... Schlenk RF.

Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure.

Leukemia (2017); 31(6): 1306-1313.

Platzbecker U, ... **Wattad M**, ... Lo-Coco F.

Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial.

J Clin Oncol (2017); 35(6): 605-612.

Jahn N, ... **Wattad M**, ... Paschka P.

Incidence and prognostic impact of ASXL2 mutations in adult acute myeloid leukemia patients with t(8;21)(q22;q22): a study of the German-Austrian AML Study Group.

Leukemia (2017); 31(4): 1012-1015.

Schlenk RF, ... **Wattad M**, ... Döhner H; the German-Austrian AMLSG.

Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia.



Leukemia (2017); 31(5): 1217-1220.

Jaramillo S, ... **Wattad M**, ... Schlenk RF.

Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia.

Blood Cancer J (2017); 7(5): e564.

Both A, ... **Wattad M**, ... Wagner K.

The hypomorphic TERT A1062T variant is associated with increased treatment-related toxicity in acute myeloid leukemia.

Ann Hematol (2017); 96 (6): 895-904.

Thol F, ... **Wattad M**, ... Heuser M.

Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis.

Leukemia (2017); 31(6): 1286-1295.

Nagel G, ... **Wattad M**, ... Schlenk RF; German-Austrian AML Study Group (AMLSG).

Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO).

Ann Hematol (2017); 96 (12): 1993-2003.

2016

Baertsch, MA, ... **Reimer, P**, ... Goldschmidt, H.

Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma.

BMC Cancer (2016); 16(1): 290.

Wilhelm, M, ... **Reimer, P**, ... Birkmann, J.

First-line therapy of peripheral T cell lymphoma: extension and long-term follow up of a study investigating the role of autologous stem cell transplantation.

Blood Cancer J (2016), 6: e452.

Fuerst D, ... **Wattad M**, ... Mytilineos J.



Matching for the MICA-129 polymorphism is beneficial in unrelated hematopoietic stem cell transplantation.

Blood (2016); 128(26): 3169-3176.

Schlenk RF, ... **Wattad M**, ... Döhner H; German-Austrian Acute Myeloid Leukemia Study Group.
All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study.

Ann Hematol (2016); 95(12): 1931-1942.

Theis F, ... **Wattad M**, ... Döhner K.

Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study group.

Leukemia (2016); 30(11): 2248-2250.

2015

Reimer, P.

New developments in the treatment of peripheral T-cell lymphoma – role of Belinostat.

Cancer Management and Research (2015); 7: 145–151.

Tassara M, ... **Wattad M**, ... Schlenk RF.

Blood (2014); 123(26): 4027-4036.

Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients.

Erratum in: Blood (2015); 125(19): 3037.

2014

Reimer, P.

Treatment options for patients with relapsing and refractory peripheral T-cell lymphoma.

Int J Hematol Oncol (2014); 3(5): 343-352.

2013



Reimer, P, Chawla, S.

Long-Term Complete Remission with Belinostat in a Patient with Chemotherapy Refractory Peripheral T-Cell Lymphoma.

J Hematol Oncol (2013); 6(69): 1-3.

Rummel, MJ, ... Brugger, W.; Study group indolent Lymphomas (StiL).

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.

Collaborators: ... **Reimer, P.**

Lancet (2013); 381(9873): 1203-1210. Erratum in: Lancet (2013); 381(9873): 1184.

Paschka P, ... **Wattad M,** ...Döhner K.

Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG).

Blood (2013); 121(1): 170-177.

Gaidzik VI, ...**Wattad M,** ... Döhner K.

Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG).

Blood (2013); 121(23): 4769-4777.

Lo-Coco F, ... **Wattad M,** ... Platzbecker U; Gruppo Italiano Malattie Ematologiche dell'Adulto; German-Austrian Acute Myeloid Leukemia Study Group; Study Alliance Leukemia.

Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.

N Engl J Med (2013); 369(2): 111-121.



Leitlinien

Hopfinger, G, Krasniqi, F, **Reimer, P**, Schmitz, N, Wulf, G,
Periphere T-Zell Lymphome.
DGHO Onkopedia Leitlinie 03/2016.

Buchbeiträge

1. **Reimer, P.**

Reife T- und NK-Zell-Neoplasien

Reimer, P.

Immundefizienzassoziierte lymphoproliferative Erkrankungen

Reimer, P.

Histiozytische Neoplasien und Neoplasien der dendritischen Zellen

In: Kreuzer, K.-A. und Beyer, J. Hämatologie und Onkologie. Georg Thieme Verlag,
Auflage, Stuttgart (2016); Kapitel 11 Hämatologische Erkrankungen: 306-309, 312-314,
315.



Gutachter wissenschaftlicher Zeitschriften

- Acta Haematologica
- Advances in Modern Oncology Research
- Annals of Hematology
- Annals of Oncology
- Biomarker Research
- Blood
- Blood Cancer Journal
- Blood and Lymphatic Cancer: Targets and Therapy
- Bone Marrow Transplantation
- Case Reports in Medicine
- Clinical Cancer Research
- Clinical Gastroenterology and Hepatology
- Clinical Lymphoma and Myeloma
- Expert Opinion on Drug Discovery
- Expert Opinion on Investigational Drugs
- Expert Review in Hematology
- Gut
- Hematological Oncology
- Journal of Hematology and Oncology
- Leukemia
- Leukemia and Lymphoma
- Oncology Research and Treatment (früher: Onkologie)
- Onkologie